Cargando…

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer

Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the prevention of HZ among adults aged ≥18 years diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curran, Desmond, Patterson, Brandon J., Carrico, Justin, Salem, Ahmed, La, Elizabeth M., Lorenc, Stéphane, Hicks, Katherine A., Poston, Sara, Carpenter, Christopher F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Zoster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038038/ https://www.ncbi.nlm.nih.gov/pubmed/36880669 http://dx.doi.org/10.1080/21645515.2023.2167907

Ejemplares similares

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

The incidence of herpes zoster in China: A meta-analysis and evidence quality assessment
por: Zhang, Zhujiazi, et al.
Publicado: (2023)

Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021)
por: Irigoyen-Mansilla, Victor-Manuel, et al.
Publicado: (2023)

Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper
por: Ramasubramanian, V, et al.
Publicado: (2023)

How to manage herpes zoster ophthalmicus
por: Tuft, Stephen
Publicado: (2020)

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
por: Han, Ru, et al.
Publicado: (2023)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Multidermatomal Herpes Zoster in immunocompromised patient
por: Park, Keon Woo, et al.
Publicado: (2020)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2022)

12. Modeled Impact of the COVID-19 Pandemic and Associated Reduced Adult Vaccinations on Herpes Zoster in the United States
por: La, Elizabeth M, et al.
Publicado: (2021)

The temporal impact of aging on the burden of herpes zoster
por: Varghese, Lijoy, et al.
Publicado: (2017)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Herpes-Zoster-Associated Voiding Dysfunction in an Immunocompromised Patient
por: Alalwan, Adel A, et al.
Publicado: (2020)

Herpes zoster ophthalmicus or Herpes zoster maxillaris?
por: Chandravanshi, Shivcharan Lal, et al.
Publicado: (2009)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

Herpes zoster segmental paresis in an immunocompromised breast cancer woman
por: Rastegar, Shirvan, et al.
Publicado: (2015)

Necrotizing Fasciitis Following Herpes Zoster Ophthalmicus in an Immunocompromised Patient
por: Cozzupoli, Grazia Maria, et al.
Publicado: (2019)

The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient
por: Kobayashi, Hiroki, et al.
Publicado: (2021)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination
por: Poirrier, Jean-Etienne, et al.
Publicado: (2022)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
por: Van Oorschot, Desirée, et al.
Publicado: (2018)

Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series
por: Terheyden, Patrick, et al.
Publicado: (2023)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

Herpes Zoster
por: Warneros Loyo, María de Lourdes
Publicado: (1995)

Herpes Zoster
Publicado: (1890)

Herpes Zoster
por: Wile, Henry
Publicado: (1886)

Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis
por: Curran, Desmond, et al.
Publicado: (2019)

Lifetime risk of herpes zoster in the population of Beijing, China
por: Lee, Christa, et al.
Publicado: (2023)

996. The Potential for Reducing Opioid and Analgesic Prescriptions Via Herpes Zoster Vaccination
por: Poirrier, Jean-Etienne, et al.
Publicado: (2020)

A systematic literature review of herpes zoster incidence worldwide
por: van Oorschot, Désirée, et al.
Publicado: (2021)

1440. Meta-regression Analysis of Worldwide Herpes Zoster Incidence
por: Yawn, Barbara P, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rb613jgqapqgua4tet1ml5r2v6